section name header

Indications

High Alert

Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, and Zirabev:

Avastin, Mvasi, Vegzelma, and Zirabev:

Avastin only:

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, hypertension, hypotension.

Derm: impaired wound healing, NECROTIZING FASCIITIS, WOUND DEHISCENCE.

EENT: nasal septum perforation.

GI: GI PERFORATION.

GU: serum creatinine, nephrotic syndrome, ovarian failure, proteinuria.

Hemat: BLEEDING, THROMBOEMBOLIC EVENTS.

Neuro: POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES).

Resp: HEMOPTYSIS.
Misc: INFUSION REACTIONS.

Interactions

Drug-Drug:

Availability

Route/Dosage

see Calculator

Colorectal Cancer

Lung Cancer or Cervical Cancer

Glioblastoma or Renal Cell Carcinoma

Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Following Surgical Resection

Hepatocellular Carcinoma

US Brand Names

Alymsys, Avastin, Avzivi, Mvasi, Vegzelma, Zirabev

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: monoclonal antibodies

Pharmacokinetics

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Unknown.

Half-life: 20 days (range 11–50 days).

Canadian Brand Names

Abevmy, Aybintio, Bambevi

Time/Action Profile

ROUTEONSETPEAKDURATION
IVrapidend of infusion14 days

Patient/Family Teaching

Pronunciation

be-va-SIZ-uh-mab